35 results on '"Peters, Bas"'
Search Results
2. Fully invertible hyperbolic neural networks for segmenting large-scale surface and sub-surface data
- Author
-
Peters, Bas, Haber, Eldad, and Lensink, Keegan
- Published
- 2024
- Full Text
- View/download PDF
3. Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non–Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy
- Author
-
Verschueren, Marjon V., Peters, Bas JM., Bloem, Lourens T., Kruik, Veerle R., Uitvlugt, Elien B., Bijsmans, Annette R., Egberts, Antoine CG., and van de Garde, Ewoudt MW.
- Published
- 2024
- Full Text
- View/download PDF
4. Fully hyperbolic convolutional neural networks
- Author
-
Lensink, Keegan, Peters, Bas, and Haber, Eldad
- Published
- 2022
- Full Text
- View/download PDF
5. Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
- Author
-
Thomas, Sarah E., Seyger, Marieke M. B., Mangnus, Josje E., Otero, Marisol E., Gostynski, Antoni H., Njoo, Marcellus D., Ossenkoppele, Paul M., Haeck, Inge M., Hendricksen-Roelofzen, Judith H. J., Körver, John E. M., Dodemont, Sharon R. P., Tupker, Ron A., Berends, Maartje A. M., Weppner-Parren, Lizelotte M. J. T., Keijsers, Romy R. M. C., Oostveen, Annet M., Peters, Bas, Mommers, Roland, van Doorn, Martijn B. A., and Tjioe, Milan
- Subjects
THERAPEUTIC use of monoclonal antibodies ,PSORIASIS ,TERMINATION of treatment ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,ODDS ratio ,RESEARCH ,CONFIDENCE intervals ,INTERLEUKINS ,EVALUATION ,CHEMICAL inhibitors - Abstract
The article focuses on evaluating real-world outcomes in psoriasis treatment when switching to interleukin-23 inhibitors (IL-23i) after ineffectiveness of ustekinumab. It explores drug survival (DS) and effectiveness of IL-23i in patients who previously discontinued ustekinumab due to ineffectiveness compared to those who had not used ustekinumab before. It uses data from the BioCAPTURE registry to analyze outcomes such as Psoriasis Area and Severity Index (PASI) scores and DS rates.
- Published
- 2024
- Full Text
- View/download PDF
6. Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry.
- Author
-
van Hal, Tamara W., van den Reek, Juul M. P. A., Wenink, Mark H., Otero, Marisol E., Ossenkoppele, Paul M., Njoo, Marcellus D., Oostveen, Annet, Peters, Bas, Tjioe, Milan, Kop, Else N., Körver, John E. M., Dodemont, Sharon R. P., Kleinpenning, Marloes M., Berends, Maartje A. M., Veldkamp, Wendelien R., van Doorn, Martijn B. A., Mommers, Johannes M., Lindhout, Robert-Jan, Kuijpers, Astrid L. A., and van Lümig, Paula P.
- Subjects
GENERALIZED estimating equations ,PSORIASIS ,ACTIVITIES of daily living ,EVERYDAY life ,LABOR productivity - Abstract
Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations. Results: We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, p<0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, p=0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12months, p=0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning. Conclusion: Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
- Author
-
Cramer-van der Welle, Christine M., Peters, Bas J. M., Deenen, Maarten J., Schramel, Franz M. N. H., and van de Garde, Ewoudt M. W.
- Published
- 2021
- Full Text
- View/download PDF
8. The potential for deprescribing in a palliative oncology patient population: a cross-sectional study.
- Author
-
van Merendonk, Lisanne N., Peters, Bas J. M., Möhlmann, Julia E., Hunting, Cornelis B., Kastelijn, Elisabeth A., and van den Broek, Marcel P. H.
- Published
- 2024
- Full Text
- View/download PDF
9. Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008–2012
- Author
-
Peters, Bas J.M., Cramer-vd Welle, Christine M., Smit, Arthur A.J., Schramel, Franz M.N.H., and van de Garde, Ewoudt M.W.
- Published
- 2017
- Full Text
- View/download PDF
10. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands
- Author
-
Reesink, Daan J., van de Garde, Ewoudt M. W., Peters, Bas. J. M., van der Nat, Paul B., Los, Maartje, Horenblas, Simon, and van Melick, Harm H. E.
- Published
- 2020
- Full Text
- View/download PDF
11. Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: A systematic review
- Author
-
Peters, Bas J.M., Janssen, Vivi E.M.T., Schramel, Franz M., and van de Garde, Ewoudt M.W.
- Published
- 2016
- Full Text
- View/download PDF
12. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population
- Author
-
Poulussen, Fenna C.P., Peters, Bas J., Hua, Ken Ho, Houthuizen, Patrick, Grouls, Rene J., and Deenen, Maarten J.
- Published
- 2019
- Full Text
- View/download PDF
13. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
- Author
-
Verschueren, Marjon V, Dijs, Talitha, Gulikers, Judith L, Veelen, Ard van, Croes, Sander, Hendriks, Lizza EL, Smit, Adrianus AJ, Bloem, Lourens T, Egberts, Antoine CG, van de Garde, Ewoudt MW, and Peters, Bas JM
- Published
- 2023
- Full Text
- View/download PDF
14. POINT-TO-SET DISTANCE FUNCTIONS FOR OUTPUT-CONSTRAINED NEURAL NETWORKS.
- Author
-
PETERS, BAS
- Subjects
NEURAL circuitry ,COMPUTER vision ,OPTIMALITY theory (Linguistics) ,BACK propagation ,MACHINE learning - Abstract
Training a neural network for semantic segmentation with many images and pixel-level segmentations is a well-established computer-vision technique. When pixel-level segmentations are unavailable, weak supervision or prior information like bounding boxes and the size/shape of objects still enables training a network. Directly including prior knowledge on the segmentations means constraining the network output. This complicates the possible optimization strategies because the regularization then acts on the non-linear neural-network function output and not on the optimization variables. We present a new algorithm to include prior information via constraints on the network output, implemented via projection-based point-to-set distance functions, that are differentiable and always have the same functional form for the derivative. Thus, there is no need to adapt penalty functions or algorithms to various constraints. The distance function's differentiability also avoids issues related to constraining properties typically associated with non-differentiable penalties. We show that by explicitly taking a general neural network structure into account, the Lagrangian for the problem 'naturally' decouples the constraints and neural network, which allows for a gradient computation via backpropagation/adjoint-state as is common in deep learning. We present a suite of constraint sets suitable for segmentation problems. The numerical experiments show that learning from constraint sets applies to the broader imaging sciences, including visual and non-visual imagery, even when training a network for a single example. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Validation of an automated method for compounding monoclonal antibody patient doses: Case studies of Avastin® (bevacizumab), Remicade® (infliximab) and Herceptin® (trastuzumab)
- Author
-
Peters, Bas J.M., Capelle, Martinus A.H., Arvinte, Tudor, and van de Garde, Ewoudt M.W.
- Published
- 2013
- Full Text
- View/download PDF
16. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
- Author
-
VAN MUIJEN, Marloes E., THOMAS, Sarah E., GROENEWOUD, Hans M. M., OTERO, Marisol E., OSSENKOPPELE, Paul M., NJOO, Marcellus D., DODEMONT, Sharon R. P., KOP, Else N., BERENDS, Maartje A. M., KOETSIER, Marjolein I. A., MOMMERS, Johannes M., KÖRVER, John E. M., TUPKER, Ron A., DE BRUIN-WELLER, Marjolein S., WEPPNERPARREN, Lizelotte J. M. T., PETERS, Bas, KLEINPENNING, Marloes M., KUIJPERS, Astrid L. A., ARNOLD, W. Peter, and VAN LÜMIG, Paula P. M.
- Subjects
PSORIASIS ,BIOLOGICALS ,RANDOMIZED controlled trials ,BIOTHERAPY ,LOGISTIC regression analysis - Abstract
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-a)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel
- Author
-
Peters, Bas JM, Harmsze, Ankie M, ten Berg, Jurriën M, Maitland-van der Zee, Anke-Hilse, Tjoeng, Mathieu M, de Boer, Anthonius, and Deneer, Vera HM
- Published
- 2011
- Full Text
- View/download PDF
18. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction
- Author
-
Peters, Bas JM, Rodin, Andrei S, Klungel, Olaf H, van Duijn, Cornelia M, Stricker, Bruno H Ch, van’t Slot, Ruben, de Boer, Anthonius, and Maitland-van der Zee, Anke-Hilse
- Published
- 2010
- Full Text
- View/download PDF
19. Genetic determinants of response to statins
- Author
-
Peters, Bas JM, Klungel, Olaf H, de Boer, Anthonius, and Maitland-van der Zee, Anke-Hilse
- Published
- 2009
- Full Text
- View/download PDF
20. How soil-borne pathogens may affect plant competition
- Author
-
Van Der Putten, Wim H. and Peters, Bas A.M.
- Subjects
Vegetation dynamics -- Research ,Plant-pathogen relationships -- Research ,Competition (Biology) -- Research ,Biological sciences ,Environmental issues ,Research - Abstract
A role for pathogens in plant competition has often been suggested, but examples are rare and, in the case of soil pathogens, virtually absent. In this paper we examine if and how soil-borne pathogens may play a role in plant competition. As a model, two successional plant species from coastal sand dunes were used: Ammophila arenaria (marram grass) and Festuca rubra ssp. arenaria (sand fescue). The root zone of A. arenaria contains pathogens that contribute to the degeneration of their host when dunes become stabilized. These pathogens (plant parasitic nematodes and pathogenic fungi) are relatively harmless to the immediate successor F. rubra. We tested the hypothesis that F. rubra, when grown in a mixed culture with A. arenaria, will be favored when A. arenaria is exposed to soil-borne pathogens from its own root zone. In a greenhouse, seedlings of both species were grown in replacement series in sterilized (pathogen-free) and unsterilized (pathogen-containing) soils originating from the root zone of natural A. arenaria. Nutrient additions, soil moisture, and the length of the experiment were based on two pilot studies. When exposed to its soil-borne pathogens, A. arenaria was outcompeted, especially when it constituted Key words: allocation; Ammophila arenaria; apparent competition; clonal plants; coastal sand dunes; Festuca rubra ssp. arenaria; fungi; host specificity; nematodes; The Netherlands; plasticity; succession., INTRODUCTION Competition is generally regarded as an important ecological factor structuring the composition and diversity of natural communities in space and time (Grace and Tilman 1990). In many cases, direct [...]
- Published
- 1997
21. Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer.
- Author
-
Cramer‐van der Welle, Christine M., Schramel, Franz M. N. H., Peters, Bas J. M., Putten, John W. G., Klungel, Olaf H., Groen, Harry J. M., and Garde, Ewoudt M. W.
- Abstract
Purpose The aim of this study is to assess how clinical outcomes in real‐world (effectiveness) correspond to the outcomes in clinical trials (efficacy) of systemic treatments for extensive disease small cell lung cancer (ED SCLC). Methods: All patients diagnosed with ED SCLC between 2008 and 2014 in six Dutch large teaching hospitals (Santeon network) were identified and followed‐up from date of diagnosis until death or end of data collection. For every patient, an efficacy‐effectiveness factor (EE factor) was calculated by dividing individual patients' overall survival (OS) by the pooled median OS assessed from clinical trials with the respective treatment. Results: From 792 diagnosed patients, 568 (72%) started with first‐line treatment. Overall, the median EE factor was 0.79 (P <.001 from 1.00). Poor performance status (ECOG≥2) and a higher age at diagnosis (age ≥ 65 years) were independent predictors for a lower EE factor. The EE gap was 43% in patients with both age ≥ 65 years and ECOG ≥2 (EE factor 0.57). The mean age and the proportion of patients with ECOG≥2 in real‐world were different from those in clinical trials (mean age of 66 versus 62 years, and ECOG≥2 25% versus 17%; both P <.001). Conclusion: OS of patients with ED SCLC treated with systemic therapy in real‐world practice is 21% shorter than for patients included in trials. Age at diagnosis and performance status partly explain this gap. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.
- Author
-
Cramer-van der Welle, Christine M., Verschueren, Marjon V., Tonn, Merel, Peters, Bas J. M., Schramel, Franz M. N. H., Klungel, Olaf H., Groen, Harry J. M., van de Garde, Ewoudt M. W., The Santeon NSCLC Study Group, Kastelijn, E. A., Vermeer, L. C., van den Borne, B. E. E. M., van Putten, J. W. G., Schouwink, J. H., and Smit, A. A. J.
- Subjects
NON-small-cell lung carcinoma ,CANCER immunotherapy ,PEMBROLIZUMAB ,FOLLOW-up studies (Medicine) - Abstract
This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer (NSCLC) in 2015–2018 in six Dutch large teaching hospitals (Santeon network) were identified and followed-up from date of diagnosis until death or end of data collection. Progression-free survival (PFS) and overall survival (OS) from first-line (1L) pembrolizumab and second-line (2L) nivolumab were compared with clinical trial data by calculating hazard ratios (HRs). From 1950 diagnosed patients, 1005 (52%) started with any 1L treatment, of which 83 received pembrolizumab. Nivolumab was started as 2L treatment in 141 patients. For both settings, PFS times were comparable between real-world and trials (HR 1.08 (95% CI 0.75–1.55), and HR 0.91 (95% CI 0.74–1.14), respectively). OS was significantly shorter in real-world for 1L pembrolizumab (HR 1.55; 95% CI 1.07–2.25). Receiving subsequent lines of treatment was less frequent in real-world compared to trials. There is no EE gap for PFS from immunotherapy in patients with stage IV NSCLC. However, there is a gap in OS for 1L pembrolizumab. Fewer patients proceeding to a subsequent line of treatment in real-world could partly explain this. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias
- Author
-
Clarke, Robert, Bennett, Derrick A., Parish, Sarah, Verhoef, Petra, Dotsch-Klerk, Mariska, Lathrop, Mark, Xu, Peng, Nordestgaard, Borge G., Holm, Hilma, Hopewell, Jemma C., Saleheen, Danish, Tanaka, Toshihiro, Anand, Sonia S., Chambers, John C., Kleber, Marcus E., Ouwehand, Willem H., Yamada, Yoshiji, Elbers, Clara, Peters, Bas, Stewart, Alexandre F.R., Reilly, Muredach M., Thorand, Barbara, Yusuf, Salim, Engert, James C., Assimes, Themistocles L., Kooner, Jaspal, Danesh, John, Watkins, Hugh, Samani, Nilesh J., Collins, Rory, and Peto, Richard
- Subjects
Meta-analysis -- Research ,Coronary heart disease -- Physiological aspects -- Development and progression ,Homocysteine -- Physiological aspects -- Health aspects ,Biological sciences - Abstract
Background: Moderately elevated blood levels of homocysteine are weakly correlated with coronary heart disease (CHD) risk, but causality remains uncertain. When folate levels are low, the TT genotype of the common C677T polymorphism (rs1801133) of the methylene tetrahydrofolate reductase gene (MTHFR) appreciably increases homocysteine levels, so 'Mendelian randomization' studies using this variant as an instrumental variable could help test causality. Methods and Findings: Nineteen unpublished datasets were obtained (total 48,175 CHD cases and 67,961 controls) in which multiple genetic variants had been measured, including MTHFR C677T. These datasets did not include measurements of blood homocysteine, but homocysteine levels would be expected to be about 20% higher with TT than with CC genotype in the populations studied. In meta-analyses of these unpublished datasets, the case-control CHD odds ratio (OR) and 95% CI comparing TT versus CC homozygotes was 1.02 (0.98-1.07;p = 0.28) overall, and 1.01 (0.95-1.07) in unsupplemented low-folate populations. By contrast, in a slightly updated meta-analysis of the 86 published studies (28,617 CHD cases and 41,857 controls), the OR was 1.15 (1.09-1.21), significantly discrepant (p = 0.001) with the OR in the unpublished datasets. Within the meta-analysis of published studies, the OR was 1.12 (1.04-1.21) in the 14 larger studies (those with variance of log OR < 0.05; total 13,119 cases) and 1.18 (1.09-1.28) in the 72 smaller ones (total 15,498 cases). Conclusions: The CI for the overall result from large unpublished datasets shows lifelong moderate homocysteine elevation has little or no effect on CHD. The discrepant overall result from previously published studies reflects publication bias or methodological problems. Please see later in the article for the Editors' Summary., Introduction Rare genetic defects that cause extremely high plasma homocysteine levels also cause coronary heart disease (CHD) [1-3]. It was therefore hypothesised that, even within the normal range of plasma [...]
- Published
- 2012
- Full Text
- View/download PDF
24. Treatment of oncogene-driven non-small cell lung cancer.
- Author
-
Kastelijn, Elisabeth A., de Langen, Adrianus J., and Peters, Bas J.M.
- Published
- 2019
- Full Text
- View/download PDF
25. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
- Author
-
de Jong, Corine, Peters, Bas J.M., and Schramel, Franz M.N.H.
- Subjects
- *
NON-small-cell lung carcinoma , *CARCINOEMBRYONIC antigen , *PNEUMONIA , *IMMUNOTHERAPY , *DRUG side effects , *DISEASE relapse - Abstract
Introduction: The introduction of immune checkpoint inhibitors heralded a new era in the treatment of non-small cell lung cancer. However, nivolumab, an anti-PD-1 antibody, can cause serious adverse events that are mostly autoimmune related. Case Presentation: A 58-year-old woman was treated with nivolumab as second-line therapy for stage IV adenocarcinoma. The patient developed a nivolumab-induced recurrent pneumonitis preceding durable clinical remission after seven cycles of nivolumab. Although high-dose glucocorticosteroids were tapered to conform to contemporary guidelines, recurring episodes of pneumonitis occurred without nivolumab rechallenge. In addition, carcinoembryonic antigen (CEA) serum levels were associated with treatment response, since CEA decline correlated with a near complete radiological response and, conversely, elevated CEA serum levels were associated with progressive disease. Conclusions: In this case, we described recurrence of nivolumab-induced pneumonitis as a serious adverse event in immune checkpoint inhibitors. Our case illustrates that immune-related adverse events may correlate with antitumour activity, even after treatment discontinuation. In addition, this case suggests the possible clinical utility of CEA serum levels for the assessment of (durable) effects of immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Methane emission reduction from storage of manure and digestate-slurry.
- Author
-
Oonk, Hans, Koopmans, Jan, Geck, Christoph, Peters, Bas, and van Bergen, Jan
- Subjects
METHANE & the environment ,GAS storage ,GREENHOUSE gas mitigation ,METHANE ,OXIDATION ,METHANOTROPHS - Abstract
Manure storage is a source of methane. An option to mitigate methane emissions from manure storage is to collect the methane produced in the storage and feed it into a dispersion layer underground. In the soil above, the methane is subsequently oxidized by methanotrophic bacteria. A previous study indicated that the method seems technically and economically feasible with costs for emission reduction of methane of €1–4 per ton CO2‐eq. mitigated. The concept was demonstrated at a pilot facility next to a storage for manure digestate and proof of concept was achieved at field scale. It was technically simple to capture methane and feed it into a dispersion system at about 1 m below the surface. Indications exist, that part of the methane was oxidised in the soil. However actual methane oxidation could not be determined, because there are serious doubts whether all methane did enter the oxidation field. For actual applications, quantification of gas generation in manure and oxidation rate of the soil need to be improved, to design an oxidation field. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
- Author
-
De Keyser, Catherine E., Peters, Bas J.m., Becker, Matthijs L., Visser, Loes E., Uitterlinden, André G., Klungel, Olaf H., Verstuyft, Céline, Hofman, Albert, Maitland-Van Der Zee, Anke-Hilse, and Stricker, Bruno H.
- Abstract
The SLCO1B1 c.521T>C polymorphism is associated with statin plasma levels and simvastatin-induced adverse drug reactions. We studied whether the c.521T>C polymorphism is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy, because these events are indicators of adverse drug reactions.We identified 1939 incident simvastatin and atorvastatin users in the Rotterdam Study, a population-based cohort study. Associations were studied using Cox proportional hazards analysis. Meta-analysis was performed with data from the Utrecht Cardiovascular Pharmacogenetics study.Simvastatin users with the c.521 CC genotype had a significantly higher risk of a dose decrease or switch than users with the TT genotype [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.05-2.88]. Female sex, age below 70 years, and low starting dose were risk factors. In atorvastatin users with starting dose of more than 20 mg, the risk of a dose decrease or switch was higher in users carrying a C allele than in users with the TT genotype (HR 3.26, 95% CI 1.47-7.25). In the meta-analysis the association in simvastatin users remained, with a significantly higher risk of a dose decrease or switch in simvastatin users with two minor alleles (HR 1.69, 95% CI 1.05-2.73). For atorvastatin users no significant association was found.In simvastatin users in the Rotterdam Study, we demonstrated an association between the c.521T>C polymorphism and dose decrease or switching, as indicators of adverse drug reactions, and provided risk factors for this association. For atorvastatin, an association was found in users with a starting dose of more than 20 mg. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
28. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
- Author
-
Peters, Bas J.M., Pett, Helmi, Klungel, Olaf H., Stricker, Bruno H. Ch., Psaty, Bruce M., Glazer, Nicole L., Wiggins, Kerri L., Bis, Josh C., de Boer, Anthonius, and Maitland-van der Zee, Anke-Hilse
- Subjects
- *
HUMAN genetic variation , *CHOLESTEROL , *STATINS (Cardiovascular agents) , *DRUG efficacy , *MYOCARDIAL infarction , *PHARMACOGENOMICS , *HOSPITAL admission & discharge , *HYPERCHOLESTEREMIA - Abstract
Abstract: Genetic variability has been shown to affect statin responsiveness. Participants from the Utrecht Cardiovascular Pharmacogenetics (UCP) studies were enrolled from a population-based registry of pharmacy records linked to hospital discharge records (PHARMO) to investigate tagging SNPs within candidate genes involved in the cholesterol lowering pathway for modification of the effectiveness of statins in reducing the risk of myocardial infarction (MI). Patients who received a prescription for an antihypertensive drug and/or had hypercholesterolemia were selected from the PHARMO database. We designed a nested case-control study in which cases were hospitalized for MI and controls were not. Patients were contacted through their community pharmacies. For this study, only hypercholesterolemic participants were selected. Logistic regression analysis was used to investigate pharmacogenetic interactions. The Heart and Vascular Health Study (HVH) was used to replicate findings from UCP. The study population included 668 cases and 1217 controls. We selected 231 SNPs of which 209 SNPs in 27 genes passed quality control. Ten SNPs in eight genes were found to influence the effectiveness of statins in UCP, of which the most significant interaction was found with SCARB1 rs4765615. Other genes that reached statistical significance (p <0.05) included two SNPs in PCSK9 (rs10888896 and rs505151 (E670G)), two SNPs in ABCG5 (rs4245786 and rs1864815), LIPC rs16940379, ABCA1 rs4149264, PPARG rs2972164, LRP1 rs715948, and SOAT1 rs2493121. None of the total of 5 SNPs that were available for replication in HVH reached statistical significance. In conclusion, ten SNPs were found to modify the effectiveness of statins in reducing the risk of MI in the UCP study. Five were also tested in the HVH study, but no interactions reached statistical significance. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
29. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction.
- Author
-
Peters, Bas J.m., Rodin, Andrei S., Klungel, Olaf H., Stricker, Bruno H.ch., De Boer, Anthonius, and Maitland-Van Der Zee, Anke-Hilse
- Abstract
To investigate the influence of tagging single-nucleotide polymorphisms (SNPs) within candidate genes involved in the putative anti-inflammatory effects of statins on the effectiveness of statins in reducing the risk of myocardial infarction (MI).We conducted a case-control study in a population-based registry of pharmacy records linked to hospital discharge records (PHARMO). Cases and controls were selected from within a hypercholesterolemic cohort. Cases were hospitalized for MI, whereas controls were not. Logistic regression analysis was used to investigate pharmacogenetic interactions.The study population comprised 668 cases and 1217 controls. We genotyped 84 SNPs in 24 genes. The effectiveness of statins was found to be modified by seven SNPs in three genes. Five out of six SNPs that were selected in the A disintegrin and metallopeptidase with thrombospondin motif type I (ADAMTS1) gene were associated with a modified response to statins, three of which were in strong linkage disequilibrium. The strongest interaction was found for ADAMTS1 rs402007. Homozygous carriers of the variant allele had the most benefit from statins [adjusted odds ratio (OR): 0.10, 95% confidence interval (CI): 0.03-0.35], compared with heterozygous (OR: 0.43, 95% CI: 0.24-0.51) and homozygous wildtype carriers (OR: 0.49, 95% CI: 0.32-0.57).Consistent with earlier findings, polymorphisms within the ADAMTS1 gene influenced the effectiveness of statins in reducing the risk of MI. Other pharmacogenetic interactions with SNPs in the TNFRSF1A and ITGB2 genes were established and the confirmation will be pursued in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
30. Methodological and statistical issues in pharmacogenomics.
- Author
-
Peters, Bas J. M., Rodin, Andrei S., De Boer, Anthonius, and Maitland-van der Zee, Anke-Hilse
- Subjects
- *
PHARMACOGENOMICS , *BIOINFORMATICS , *HUMAN genetic variation , *ANTIRETROVIRAL agents , *ABACAVIR - Abstract
Pharmacogenomics strives to explain the interindividual variability in response to drugs due to genetic variation. Although technological advances have provided us with relatively easy and cheap methods for genotyping, promises about personalised medicine have not yet met our high expectations. Successful results that have been achieved within the field of pharmacogenomics so far are, to name a few, HLA-B*5701 screening to avoid hypersensitivity to the antiretroviral abacavir, thiopurine S-methyltransferase ( TPMT) genotyping to avoid thiopurine toxicity, and CYP2C9 and VKORC1 genotyping for better dosing of the anticoagulant warfarin. However, few pharmacogenetic examples have made it into clinical practice in the treatment of complex diseases. Unfortunately, lack of reproducibility of results from observational studies involving many genes and diseases seems to be a common pattern in pharmacogenomic studies. In this article we address some of the methodological and statistical issues within study design, gene and single nucleotide polymorphism (SNP) selection and data analysis that should be considered in future pharmacogenomic research. First, we discuss some of the issues related to the design of epidemiological studies, specific to pharmacogenomic research. Second, we describe some of the pros and cons of a candidate gene approach (including gene and SNP selection) and a genome-wide scan approach. Finally, conventional as well as several innovative approaches to the analysis of large pharmacogenomic datasets are proposed that deal with the issues of multiple testing and systems biology in different ways. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
31. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study.
- Author
-
Maitland-Van Der Zee, Anke-Hilse, Peters, Bas J.m., Lynch, Amy I., Boerwinkle, Eric, Arnett, Donna K., Cheng, Suzanne, Davis, Barry R., Leiendecker-Foster, Catherine, Ford, Charles E., and Eckfeldt, John H.
- Abstract
Pharmacogenetic research has shown that genetic variation may influence statin responsiveness. Statins exert a variety of beneficial effects beyond lipid lowering, including antithrombotic effects, which contribute to the risk reduction of cardiovascular disease. Statins have been shown to influence the expression of coagulation factors II, V, VII, XII and XIII.Data from a large randomized clinical trial of pravastatin, designed to show efficacy relative to usual care, were used to investigate whether a pharmacogenetic effect of polymorphisms in genes coding for coagulation factors II, V, VII, XII and XIII is associated with reduced fatal coronary heart disease (CHD) and nonfatal myocardial infarction, combined CHD and all-cause mortality.The Genetics of Hypertension Associated Treatment is an ancillary study of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. The genotyped population in the lipid-lowering trial of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial included 9624 participants randomly assigned to pravastatin or to usual care. The efficacy of pravastatin in reducing risk of all-cause mortality, CHD and nonfatal myocardial infarction and combined CHD, was compared among genotype strata by examining an interaction term in a proportional hazards model.None of the polymorphisms were associated with the clinical outcomes. For the F7 (-323) ins/del polymorphism there was no interaction with pravastatin for either outcome. For both the F5 Arg506Gln G>A (rs6025) polymorphism and F7 Arg353Gln G>A (rs6046) polymorphism there were no interactions with pravastatin in relation to all-cause mortality, but there were significant interactions with combined CHD [interaction hazard ratio = 1.33, 95% confidence interval (1.01-1.76) and interaction hazard ratio = 1.92, 95% confidence interval (1.00-3.65), respectively]. There were no interactions between the polymorphisms in the other coagulation genes and pravastatin in relation to any outcome.Polymorphisms in anticoagulation genes (F5 and F7) seem to modify the efficacy of pravastatin in reducing risk of cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
32. Pharmacogenomic importance of pravastatin.
- Author
-
Peters, Bas and Maitland-van der Zee, Auke-Hilse
- Subjects
PHARMACOGENOMICS ,PRAVASTATIN ,STATINS (Cardiovascular agents) ,ANTICHOLESTEREMIC agents ,CARDIOVASCULAR diseases - Abstract
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly prescribed to reduce risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the interindividual variation in the response to pravastatin. This article reviews the most important studies conducted on the pharmacogenetics of pravastatin. Currently there is no evidence to advocate pharmacogenetic testing before initiating therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
33. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant.
- Author
-
Peters, Bas J.m., Maitland-Van Der Zee, Anke-Hilse, Stricker, Bruno H.ch., Van Wieren-De Wijer, Diane B.m.a., De Boer, Anthonius, Kroon, Abraham A., De Leeuw, Peter W., Schiffers, Paul, Janssen, Rob G.j.h., Van Duijn, Cornelia M., and Klungel, Olaf H.
- Abstract
The GNB3 C825T polymorphism has been shown to affect lipid parameters, atherosclerosis progression, and incidence of myocardial infarction (MI). Therefore, we assessed whether the effectiveness of statins in reducing the risk of MI was modified by the GNB3 C825T polymorphism.In a population-based registry of pharmacy records linked to hospital discharge records (PHARMO), we used a nested case-control design. We selected patients hospitalized for MI as cases if they used antihypertensive drugs and had a diagnosis of hypercholesterolemia before their first MI. Controls met the same eligibility criteria, but were not hospitalized for MI. Logistic regression analysis was used to calculate odds ratios (OR) and synergy index with corresponding 95% confidence intervals (CI), and to adjust for potential confounding factors.We included 459 cases and 1805 controls. The risk of MI was significantly lower among participants exposed to statins compared with participants not exposed to statins (adjusted OR: 0.37, 95% CI: 0.29-0.47). The GNB3T allele was associated with a reduced risk of MI (adjusted OR: 0.74, 95% CI: 0.60-0.92). Among homozygous wild-type (CC) individuals (n=1119), exposure to statins was associated with a lower risk of MI (OR: 0.48, 95% CI: 0.34-0.67). However, T allele carriers (CT and TT) who used statins had an even stronger reduced risk of MI (OR: 0.27, 95% CI: 0.19-0.39). Overall, the interaction between exposure to statins and the GNB3 C825T polymorphism was significantly increased on the multiplicative scale (synergy index: 1.67, 95% CI: 1.06-2.65).Our findings show that T allele carriers of the GNB3 C825T polymorphism have less risk of MI and are more likely to benefit from statin therapy in a hypercholesterolemic population of antihypertensive drug users. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
34. Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients.
- Author
-
Peters, Bas J. M., Bhatoe, Anish, Vorselaars, Adriane D. M., Veltkamp, Marcel, and Calender, Alain
- Subjects
- *
SARCOIDOSIS , *INFLIXIMAB , *TERMINATION of treatment , *PHYSICAL mobility , *ADALIMUMAB - Abstract
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade® or Inflectra® to Flixabi® in patients with severe refractory sarcoidosis. This single center retrospective cohort study was performed at St Antonius Hospital Nieuwegein, The Netherlands. All patients diagnosed with severe refractory sarcoidosis receiving Remicade® or Inflectra® switched to Flixabi®. The primary outcome was infliximab discontinuation within 6 months of switching. Secondary endpoints included adverse events and loss of clinical, functional, or inflammatory response. Out of 86 patients who switched to Flixabi®, 79 patients had complete data. None of the 79 patients discontinued infliximab during the first 6 months after switching. Five patients reported an adverse event related to Flixabi® treatment. We found no change from baseline in FVC, FEV1, DLCOc, 6MWT, and infliximab trough levels 26 weeks after switching. An improvement in physical functioning of 7.3 ± 13.4 points (p = 0.002) with RAND/SF36 and in biomarker sIL-2R (−475.58 ± 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade® or biosimilar infliximab Inflectra® to biosimilar infliximab Flixabi® did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014.
- Author
-
Cramer-van der Welle, Christine M., Peters, Bas J. M., Deenen, Maarten J., Schramel, Franz M. N. H., and van de Garde, Ewoudt M. W.
- Abstract
The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). All patients diagnosed (in 2008–2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years ( p = 0.437 andp = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011–2014 compared with 2008–2010.This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years. [ABSTRACT FROM AUTHOR] - Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.